ChinaAMC Hang Seng Hong Kong Biotech Index ETF Disclaimer

華夏恒生香港生物科技指數ETF免責聲明

 

投資涉及風險,包括損失本金。過往表現並不代表未來業績。投資華夏恒生香港上市生物科技指數ETF (「本基金」)前,投資者應參閱基金章程,包括細閱風險因素。閣下不應僅依賴本資料作出投資決定。請注意:

  • 本基金投資目標為提供緊貼恒生香港生物科技指數(「指數」) 表現的投資回報(未計費用及開支)。
  • 本基金以被動方式管理,基金經理將沒有酌情權適應市場變化。指數下跌預期會導致本基金價值相應下跌。
  • 本基金投資於股本證券須承受一般市場風險。其價值可能因為各種因素波動。
  • 由於指數是一隻新的指數,本基金可能會較其他追蹤具有更長運營歷史指數的基金面臨更高風險。
  • 本基金追蹤生物科技公司及特定的地區(即中華人民共和國及香港) 的表現,故面臨集中性風險,其波幅很可能超過覆蓋廣泛的基金。
  • 本基金須承受與生物科技公司特徵相關的風險,例如尚未有營業收入,淨流動負債的產生,流動性較低,波動性較高,對知識產權或專利的依賴,技術變化,法規增加以及競爭激烈。
  • 本基金涉及跟蹤誤差風險。跟蹤誤差可能由所使用的投資策略以及費用和支出導致。
  • 一般而言,散戶投資者僅可於香港聯交所買賣本基金的基金單位,而基金單位於香港聯交所的交易價格受市場因素影響,如基金單位的供求情況。因此,基金單位的交易價格可能會較本基金的資產淨值大幅溢價或折讓。

Investment involves risks, including the loss of principle. Past performance is not indicative of future results. Before investing in the ChinaAMC Hang Seng Hong Kong-Listed Biotech Index ETF (the “Fund”), investor should refer to the Fund’s prospectus for details, including the risk factors. You should not make investment decision based on the information on this material alone. Please note:

  • The Fund aims to provide investment result that, before fees and expenses, closely corresponds to the performance of the Hang Seng Hong Kong-Listed Biotech Index (the “Index”).
  • The Fund is passively managed and the Manager will not have the discretion to adapt to market changes. Falls in the Index are expected to result in corresponding falls in the value of the Fund.
  • The Fund’s investment in equity securities is subject to general market risks, whose value may fluctuate due to various factors.
  • The Index is a new index. The Fund may be riskier than those tracking more established indices with longer operating history.
  • The Fund is subject to concentration risks in biotech companies and in a particular geographical region (i.e. Hong Kong and PRC). The Fund may be more volatile than a broadly-based fund.
  • The Fund is exposed to risks associated with characters of biotech companies, such as pre-revenue, incurrence of net current liabilities, lower liquidity, higher volatility, dependency on intellectual property rights or patents, technological changes, increased regulations and intense competition.
  • The Fund is subject to tracking error risk, which may result from the investment strategy used, and fees and expenses.
  • Generally, retail investors can only buy or sell units of the Fund on the SEHK. The trading price of the units on the SEHK is driven by market factors such as the demand and supply of the units. Therefore, the units may trade at a substantial premium or discount to the Fund’s NAV.

恒生指數有限公司免責條款

恒生香港上市生物科技指數(“該指數”)由恒生資訊服務有限公司全權擁有,並已授權恒生指數有限公司發佈及編制。恒生指數有限公司及恒生資訊服務有限公司已同意華夏基金(香港)有限公司可就華夏恒生香港生物科技指數ETF(“該產品”)使用及參考該指數,但是,恒生指數有限公司及恒生資訊服務有限公司並不就該指數及其計算或任何與之有關的數據的準確性或完整性,而向任何人士作出保證或聲明或擔保,也不會就該指數提供或默示任何保證、聲明或擔保。恒生指數有限公司及恒生資訊服務有限公司不會因華夏基金(香港)有限公司就該產品使用及/或參考該指數,或恒生指數有限公司在計算該指數時的任何失準、遺漏、失誤或錯誤導致任何人士因上述原因而直接或間接蒙受的任何經濟或其他損失承擔任何責任或債務。 任何就該產品進行交易的人士不應依賴恒生指數有限公司及恒生資訊服務有限公司,亦不應以任何形式向恒生指數有限公司及/或恒生資訊服務有限公司進行索償或法律訴訟。爲免疑慮,本免責聲明不構成任何經紀或就該產品進行交易的其他人士與恒生指數有限公司及/或恒生資訊服務有限公司之間的任何合約或準合約關係,也不應視作已構成這種關係。

Hang Seng Indexes Company Limited Disclaimer

The mark and name “Hang Seng Hong Kong-Listed Biotech Index” is proprietary to Hang Seng Data Services Limited (“HSDS”) which has licensed its compilation and publication to Hang Seng Indexes Company Limited (“HSIL”).  HSIL and HSDS have agreed to the use of, and reference to, the Hang Seng Hong Kong-Listed Biotech Index by China Asset Management (Hong Kong) Limited (“the Issuer”) in connection with the ChinaAMC Hang Seng Hong Kong Biotech Index ETF (the “Product”).  However, neither HSIL nor HSDS warrants, represents or guarantees to any person the accuracy or completeness of the Hang Seng Hong Kong-Listed Biotech Index, its computation or any information related thereto and no warranty, representation or guarantee of any kind whatsoever relating to the Hang Seng Hong Kong-Listed Biotech Index is given or may be implied.  Neither HSIL nor HSDS accepts any responsibility or liability for any economic or other loss which may be directly or indirectly sustained by any person as a result of or in connection with the use of and/or reference to the Hang Seng Hong Kong-Listed Biotech Index by the Issuer in connection with the Product, or any inaccuracies, omissions or errors of HSIL in computing the Hang Seng Hong Kong-Listed Biotech Index.  Any person dealing with the Product shall place no reliance whatsoever on HSIL and/or HSDS nor bring any claims or legal proceedings against HSIL and/or HSDS in any manner whatsoever.  For the avoidance of doubt, this disclaimer does not create any contractual or quasi-contractual relationship between any broker or other person dealing with the Product and HSIL and/or HSDS and must not be construed to have created such relationship.

重要信息

  • 本資料僅供指定收件人之資訊及參考之用,幷不構成投資於任何證券的邀約。本資料有關基金的內容不適用於在限制該內容之發佈的區域居住之人士。任何人士均不得視本資料為構成購買或認購參與基金股份的要約或邀請,也不得在任何情況下使用基金認購協定,除非在相關司法管轄區內該邀約和分發是合法的。非香港投資者有責任遵守其相關司法管轄區的所有適用法律法規,然後繼續閱讀本資料所包含的資訊。
  • 本資料所載之資訊僅反映現時市場狀況及我們於編制材料當日的判斷,幷可隨時因隨後情況變化而更改,恕不另行通知。於製作本檔時,本公司依賴及假設公共媒介提供的資料的正確性及完整性。本公司認為本檔的所得資料為可靠的;然而,本公司幷不保證該資料的完整性及正確性。華夏基金(香港)或其聯營公司、董事及雇員概不對於本檔內所提供之資訊的任何錯誤或遺漏負上任何責任,幷且本公司不應就任何人士因依賴或使用該等資料而招致的任何損失負責。
  • 投資涉及風險。過往業績不代表將來表現。基金價格及其收益可升可跌,幷不能保證。投資價值亦可能受到匯率影響。投資者可能無法取回原本的投資金額。
  • 本資料並未經香港證監會審閱。發佈人:華夏基金(香港)有限公司。在未經華夏基金(香港)有限公司同意前,不得複印,分發或複製本資料或本資料內任何部份內容給予預定收件人以外的任何人士。
  • 本演示文稿由華夏基金(香港)有限公司編寫,僅供指定收款人內部使用。

Important Information

  • Investment involves risks. Past performance is not indicative of future performance, future return is not guaranteed and a loss of your original capital may occur. This material does not constitute an offer or solicitation of any transaction in any securities or collective investment schemes, nor does it constitute any investment advice.
  • This presentation is prepared by China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)”) and is intended only for the internal use of the recipient(s) for information purposes and should not be distributed to any other end investors. This document is provided for information purpose only and shall not be relied upon for making any investment decision. This presentation does not constitute a distribution or an offer to invest in any securities, nor does it constitute any investment advice or recommendation to acquire or dispose of any securities or enter into any transactions. This presentation does not take account of your investment strategies, financial and personal status. This presentation does not guarantee nor promise the effectiveness of any investment strategies listed and the attainable investment returns. Before taking actions, you should consider your personal suitability for such investment, securities or investment strategies. If necessary, you should seek independent professional advice.
  • The information in this material reflects prevailing market condition and our judgment as of this date, which are subject to change, we are not obliged to inform you of such change. Certain information or data in this document has been obtained from unaffiliated third parties; we have reasonable belief that such information or data is accurate, complete and up to the date as indicated, but we make no warranty or representation as to the completeness and accuracy of data and information sourced from such unaffiliated third parties. ChinaAMC (HK), its affiliates, directors, officers or employees will not be liable for any damages or costs arising out of or in any way connected with the use of the information contained herein. This material is produced by ChinaAMC (HK); none of the information in this material can be reproduced or published without the consent of ChinaAMC (HK).
  • This presentation has not been reviewed by the SFC. Please refer to the prospectus of funds for more details, including risk factors. If you are in any doubt about the content of this presentation, you should obtain independent professional advice.
  • This presentation is prepared by China Asset Management (Hong Kong) Limited (“ChinaAMC (HK)”) and is intended only for the internal use of the designated recipient(s) and professional investor(s) only.